These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

708 related items for PubMed ID: 12671459

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Immunopathology of RSV infection: prospects for developing vaccines without this complication.
    van Drunen Littel-van den Hurk S, Mapletoft JW, Arsic N, Kovacs-Nolan J.
    Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prevention and treatment of respiratory syncytial virus infection in infants: an update.
    Venkatesh MP, Weisman LE.
    Expert Rev Vaccines; 2006 Apr; 5(2):261-8. PubMed ID: 16608425
    [Abstract] [Full Text] [Related]

  • 6. Prevention strategies for respiratory syncytial virus: passive and active immunization.
    Englund JA.
    J Pediatr; 1999 Aug; 135(2 Pt 2):38-44. PubMed ID: 10431138
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.
    Johnson TR, Graham BS.
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S46-57. PubMed ID: 14730270
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis.
    Harcourt JL, Karron RA, Tripp RA.
    J Infect Dis; 2004 Dec 01; 190(11):1936-40. PubMed ID: 15529257
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus.
    Shinoff JJ, O'Brien KL, Thumar B, Shaw JB, Reid R, Hua W, Santosham M, Karron RA.
    J Infect Dis; 2008 Oct 01; 198(7):1007-15. PubMed ID: 18702606
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Basic epidemiology and immunopathology of RSV in children.
    Handforth J, Friedland JS, Sharland M.
    Paediatr Respir Rev; 2000 Sep 01; 1(3):210-4. PubMed ID: 12531081
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.
    Langley JM, Sales V, McGeer A, Guasparini R, Predy G, Meekison W, Li M, Capellan J, Wang E.
    Vaccine; 2009 Sep 25; 27(42):5913-9. PubMed ID: 19651171
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.